MELBOURNE, Australia and SAN FRANCISCO, April  16, 2026  (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) (&#34;Alterity&#34; or &#34;the Company&#34;), a biotechnology company dedicated to developing disease modifying

ATHE

Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting

Alterity Therapeutics to Present Key Data on ATH434 at AAN Conference

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 MELBOURNE, Australia and SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) (&amp;#34;Alterity&amp;#34; or &amp;#34;the Company&amp;#34;), a biotechnology company dedicated to developing disease modifying
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 Alterity Therapeutics will present critical data on its drug ATH434 at the AAN Annual Meeting, highlighting its efficacy in treating Multiple System Atrophy. This presentation could drive investor interest and influence the upcoming Phase 3 trial decisions, pivotal for the company&#039;s future.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>Alterity Therapeutics presents at AAN 2026 conference.</li><li>Presentation discusses ATH434&#039;s efficacy in Multiple System Atrophy.</li><li>Company preparing for Phase 3 trial for MSA.</li><li>Positive Phase 2 trial results reported for ATH434.</li><li>Event scheduled for April 21, 2026 at 6:21 PM CT.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>Alterity Therapeutics (ATHE): Upcoming conference may bolster investor confidence and share valuation.</li></ul>
 </section>

 <section data-block="category">
 <h3>Corporate Developments</h3>
 This news falls under &#039;Corporate Developments&#039; as it concerns ongoing clinical advancements, which influence investor sentiment significantly within biotech sectors.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>Presentation could result in increased investor interest and share price.</li><li>Positive data may catalyze preparation for upcoming funding rounds.</li><li>Market response influenced by competitive positioning against other neurodegenerative drugs.</li><li>Timing of Phase 3 initiation could attract attention from institutional investors.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>AAN Annual Meeting: April 18-22, 2026.</li><li>Presentation on ATH434 scheduled for April 21, 2026.</li><li>ATH434 shows positive Phase 2 trial results.</li><li>Company transitioning to Phase 3 trials for MSA.</li><li>Alterity Therapeutics based in Melbourne and San Francisco.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 ATHE shares likely to see upward momentum leading to the AAN conference.
 </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link>MELBOURNE, Australia and SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2u9_nfluKZy620WKDNCgnglGLHm9VlQGXE56a_RK6FGEHI2Gf6zGcN_iegbwyqoqVuSr4EZS-82qHjSg2tWflieqq2RqRSMj2aJevt7gdvc=" rel="nofollow" target="_blank">Alterity Therapeutics</a> ((ASX: ATH, NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ATHE">ATHE</a>) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical Center and Chief Medical Advisor for Alterity, will deliver an oral presentation during a Late Breaking Session at the American Academy of Neurology (AAN) Annual Meeting taking place April 18-22, 2026 in Chicago, IL, USA. <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:15%; width:15%; min-width:15%;">Session: </td><td style="max-width:85%; width:85%; min-width:85%;">Late-breaking Science 2</td></tr><tr><td>Type:</td><td>Oral Presentation</td></tr><tr><td>Title:</td><td>ATH434 Demonstrates Disease-Modifying Signal in Multiple System Atrophy Using the MuSyCA Composite Scale</td></tr><tr><td>Date/Time:</td><td>Tuesday, April 21, 2026, 6:21 PM CT</td></tr></table> About Alterity Therapeutics Limited  Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company's lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company's website at <a href="https://www.globenewswire.com/Tracker?data=pySAumDXqjxRO8M6fFPNqZbIMbV8ITZef2-bXsrfrw-SauoCobC8is3hXHPhJB2HzmkzwqEJ7zNPkUHoFIqH01lj1T1vQW3IdTN1ajHP8kQ=" rel="nofollow" target="_blank">https://alteritytx.com</a>. Authorisation &amp; Additional information This announcement was authorized by the Board of Alterity Therapeutics Limited. Contacts: Investors: Elyse Shapiro <a href="https://www.globenewswire.com/Tracker?data=rsCu6GIGTZZgPelvG4tik7xEyzOUKWDYXHp0AmtzUYnIKfKzrpp7N3iLMvWekbGMSJbxxfG2N8X9qvDbIWjkY265x0jnhZ-k7uz1OA7jIT0=" rel="nofollow" target="_blank">ir@alteritytx.com</a> Remy Bernarda Investor Relations Advisory Solutions <a href="https://www.globenewswire.com/Tracker?data=rsCu6GIGTZZgPelvG4tik7vKOs76Se9COvofDdO6vAXszP3k-4Tl3GpBnGCT7cl9u_EjTaWtLTcT4ovlS6atczNnU9GXuLK_UM_3lhJ-zo8=" rel="nofollow" target="_blank">ir@alteritytx.com</a> +1 (415) 203-6386 Media Casey McDonald Tiberend Strategic Advisors, Inc. <a href="https://www.globenewswire.com/Tracker?data=THeic_5GgO_-3uCW5b_FbfFSROjF-NnPeXqOVnkIltxetgmJAAjf6S14asCZQjtbFrwc2diC30ADJaV_fSyugrOeaTO5u903DpLPogv71D4=" rel="nofollow" target="_blank">cmcdonald@tiberend.com</a> +1 (646) 577-8520 Forward Looking Statements This press release contains &#34;forward-looking statements&#34; within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as &#34;expects,&#34; &#34;intends,&#34; &#34;hopes,&#34; &#34;anticipates,&#34; &#34;believes,&#34; &#34;could,&#34; &#34;may,&#34; &#34;evidences&#34; and &#34;estimates,&#34; and other similar expressions, but these words are not the exclusive means of identifying such statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled "Risk Factors" in the Company's filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company&#39;s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company&#39;s drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company&#39;s drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company&#39;s intellectual property or trade secrets, the uncertainty of successfully enforcing the Company's patent rights and the uncertainty of the Company freedom to operate. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY5MTA1MSM3NTM4ODEzIzIyNTY3MTM="></img> <img alt="" src="https://ml.globenewswire.com/media/ZmZlM2QzYWQtN2M4YS00ZjU0LTkxMDctOWYyNDY2MTkzZjk0LTEyNjgyNjItMjAyNi0wNC0xNi1lbg==/tiny/ALTERITY-THERAPEUTICS-LIMITED.png" referrerpolicy="no-referrer-when-downgrade"></img><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/0771a9a2-2ac1-4a63-9767-a2b1df74af27"><img src="https://ml.globenewswire.com/media/0771a9a2-2ac1-4a63-9767-a2b1df74af27/small/alterity-png.png" border="0" width="150" height="38" alt="Primary Logo"></img></a>

Alterity Therapeutics will present critical data on its drug ATH434 at the AAN Annual Meeting, highlighting its efficacy in treating Multiple System Atrophy. This presentation could drive investor interest and influence the upcoming Phase 3 trial decisions, pivotal for the company's future.

Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News